Filing Flows

Filing Flows › Ocular Therapeutix (OCUL) › Next earnings date

Ocular Therapeutix (OCUL) earnings on Nov 9, 2026: what to expect

Ocular Therapeutix (OCUL) is expected to report earnings on Nov 9, 2026, tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.35 (−$0.37 to −$0.30, 6 estimates) on revenue of $14.3M, against −$0.38 and $14.5M a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 64% chance of beating next time.

Report dateNov 9, 2026
Days to go1
EPS estimate−$0.35
Revenue estimate$14.3M
Beat rate50%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Ocular Therapeutix: revenue lines, growth year over year, Q2 2026Ocular Therapeutix: revenue lines, growth year over year, Q2 2026Revenue+0.1%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.38 on revenue of $15.0M, against the analysts' −$0.35.

The last report

Ocular Therapeutix reported revenue of $13.5M for the second quarter 2026 (+0.1% Y/Y), net loss $78.8M. How it makes money → · Every quarter →

Ocular Therapeutix: EPS against the estimate, last 4 reportsOcular Therapeutix: EPS against the estimate, last 4 reportsEstimateReported−$0.35−$0.38Nov 25−$0.34−$0.29Feb 26−$0.32−$0.40May 26−$0.39−$0.35Aug 26
Latest (Aug 26): Estimate −$0.39, Reported −$0.35.

Ocular Therapeutix's latest quarter

Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.

Questions

When does OCUL report earnings?

Ocular Therapeutix is expected to report on Nov 9, 2026.

What are analysts expecting from Ocular Therapeutix?

EPS of −$0.35 and revenue of $14.3M for the quarter.

Does Ocular Therapeutix usually beat earnings?

It beat the consensus EPS estimate in 50% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.